These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22202150)

  • 1. The magic-bullet: moving the concept towards reality – part II.
    Elgqvist J
    Curr Radiopharm; 2011 Oct; 4(4):281-2. PubMed ID: 22202150
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential and pitfalls of therapy with alpha-particles.
    Welch MJ
    J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland.
    Zalutsky MR; Petelenz B
    Nucl Med Rev Cent East Eur; 2004; 7(2):195. PubMed ID: 15968616
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted α-Therapy.
    Brechbiel MW
    Cancer Biother Radiopharm; 2020 Aug; 35(6):397. PubMed ID: 32503377
    [No Abstract]   [Full Text] [Related]  

  • 6. Higher relative biological efficiency of alpha-particles: in vitro veritas, in vitro vanitas?
    Behr TM; Béhé M; Jungclas H; Jungclas H; Becker W; Sgouros G
    Eur J Nucl Med; 2001 Sep; 28(9):1435-6. PubMed ID: 11585306
    [No Abstract]   [Full Text] [Related]  

  • 7. Higher relative biological efficiency of alpha-particles: in vitro veritas, in vivo vanitas?
    Behr TM
    Eur J Nucl Med; 2001 Jul; 28(7):939-40. PubMed ID: 11504094
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted alpha therapy with 213Bi.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
    Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
    Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alpha edge?
    Silberstein EB
    Oncology (Williston Park); 2012 Apr; 26(4):345, 348. PubMed ID: 22655527
    [No Abstract]   [Full Text] [Related]  

  • 11. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radium-223: down to the bone, and less is more.
    Chang AJ; Roach M
    Oncology (Williston Park); 2012 Apr; 26(4):342, 344. PubMed ID: 22655526
    [No Abstract]   [Full Text] [Related]  

  • 13. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.
    Sgouros G; Hobbs R; Josefsson A
    Curr Radiopharm; 2018; 11(3):209-214. PubMed ID: 29697036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates.
    Dahle J; Abbas N; Bruland ØS; Larsen RH
    Curr Radiopharm; 2011 Oct; 4(4):321-8. PubMed ID: 22202154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radionuclide antibody-conjugates, a targeted therapy towards cancer.
    Kitson SL; Cuccurullo V; Moody TS; Mansi L
    Curr Radiopharm; 2013 Jun; 6(2):57-71. PubMed ID: 23808764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and perspectives in alpha radioimmunotherapy.
    Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
    Pozzi OR; Zalutsky MR
    J Nucl Med; 2005 Aug; 46(8):1393-400. PubMed ID: 16085599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
    Radchenko V; Schaffer P; Knapp FFR
    Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
    [No Abstract]   [Full Text] [Related]  

  • 19. Pretargeted radioimmunotherapy with α-particle emitting radionuclides.
    Lindegren S; Frost SH
    Curr Radiopharm; 2011 Jul; 4(3):248-60. PubMed ID: 22201711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of Ac225 vs Bi213 as therapeutic radioisotopes for targeted alpha therapy for cancer.
    Allen BJ
    Australas Phys Eng Sci Med; 2017 Jun; 40(2):369-376. PubMed ID: 28342027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.